RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Our drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types. We hold an exclusive license from Columbia University for its RyR technology based on the research of our founder, Dr. Andrew Marks. RyCarma’s lead candidate, ARM210, is in development for the treatment of heart failure and ryanodine receptor 1-related myopathies (RYR1-RM).
Company Details
- Employees
- 8
- Address
- Manager Jobs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.rycarma.com
- Keywords
- on ryanodine receptors (RyRs).
Rycarma Therapeutics Questions
Rycarma Therapeutics's website is http://www.rycarma.com
Rycarma Therapeutics's LinkedIn profile is https://www.linkedin.com/company/rycarma
Rycarma Therapeutics has
8 employees.
View email and phone details for 8
employees at Rycarma Therapeutics.
Rycarma Therapeutics's industry is
Biotechnology Research
Rycarma Therapeutics's top competitors are
Flagship Pioneering,
Evercore,
Rodin Therapeutics,
Vectory,
Seamless Therapeutics,
Forbion,
Ambagon Therapeutics,
Azafaros B.v.,
Aeglea Biotherapeutics,
Kynexis.
Rycarma Therapeutics's categories are Biotechnology Research
